Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) is 1.32% higher on its value in year-to-date trading and has touched a low of $9.56 and a high of $31.46 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ZNTL stock was last observed hovering at around $14.78 in the last trading session, with the day’s gains setting it 0.57%.
Currently trading at $15.35, the stock is 9.55% and 12.38% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.08 million and changing 3.82% at the moment leaves the stock -20.41% off its SMA200. ZNTL registered -9.28% loss for a year compared to 6-month loss of -37.85%. The firm has a 200-day simple moving average (SMA200) of -$2.57.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 33.48% gain in the last 1 month and extending the period to 3 months gives it a 19.92%, and is 5.28% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.01% over the week and 8.38% over the month.
Zentalis Pharmaceuticals Inc (ZNTL) has around 168 employees, a market worth around $1.09B and $0.00M in sales. Distance from 52-week low is 60.56% and -51.21% from its 52-week high. The company has generated returns on investments over the last 12 months (-60.82%).
Zentalis Pharmaceuticals Inc quarterly earnings per share for the current quarter are estimated at -$0.77 with sales reaching $13.12M over the same period.The EPS is expected to grow by 18.03% this year
182 institutions hold shares in Zentalis Pharmaceuticals Inc (ZNTL), with institutional investors hold 119.95% of the company’s shares. The shares outstanding are 70.77M, and float is at 63.83M with Short Float at 22.81%. Institutions hold 114.88% of the Float.
The top institutional shareholder in the company is Matrix Capital Management with over 13.96 million shares valued at $393.81 million. The investor’s holdings represent 19.73% of the ZNTL Shares outstanding. As of Jun 29, 2023, the second largest holder is FMR, LLC with 10.58 million shares valued at $298.37 million to account for 14.95% of the shares outstanding. The other top investors are Eventide Asset Management LLC which holds 6.88 million shares representing 9.72% and valued at over $194.02 million, while Vanguard Group Inc holds 6.97% of the shares totaling 4.93 million with a market value of $139.05 million.
Zentalis Pharmaceuticals Inc (ZNTL) Insider Activity
The most recent transaction is an insider sale by Epperly Melissa B,, the company’s Chief Financial Officer. SEC filings show that Epperly Melissa B, sold 2,573 shares of the company’s common stock on Feb 12 ’24 at a price of $11.44 per share for a total of $29435.0. Following the sale, the insider now owns 0.45 million shares.
Zentalis Pharmaceuticals Inc disclosed in a document filed with the SEC on Feb 12 ’24 that Gallagher Cam (President) sold a total of 1,173 shares of the company’s common stock. The trade occurred on Feb 12 ’24 and was made at $11.44 per share for $13419.0. Following the transaction, the insider now directly holds 0.64 million shares of the ZNTL stock.
Still, SEC filings show that on Feb 02 ’24, Gallagher Cam (President) disposed off 11,552 shares at an average price of $11.54 for $0.13 million. The insider now directly holds 644,450 shares of Zentalis Pharmaceuticals Inc (ZNTL).
